Lead­ing health­care agency notch­es dou­ble-dig­it growth for first half, dri­ven by dig­i­tal shifts and full pipelines

While the ad in­dus­try is nav­i­gat­ing a jit­tery econ­o­my — and the loom­ing threat of mar­ket­ing bud­get cuts — the phar­ma sec­tor seems to be hum­ming along. One proof point this week is Re­al Chem­istry, the sec­ond-largest health­care agency in North Amer­i­ca, with a healthy first-half re­port and dou­ble-dig­it growth.

The dig­i­tal com­mu­ni­ca­tions and mar­ket­ing com­pa­ny re­port­ed on Wednes­day’s first half rev­enues of more than $270 mil­lion, a 21% in­crease com­pared to the first half of 2021. While the 2022 jump won’t sur­pass the pan­dem­ic af­fect­ed 2020 to 2021 in­crease of 35%, Re­al Chem­istry CEO Shankar Narayanan said it’s pro­ject­ing full-year growth of 20%. Re­al Chem­istry notched $439 mil­lion in 2021 sales, putting the pro­ject­ed 2022 full year at more than $525 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER